Title:
TREATMENT OF IMMUNE DISORDERS
Document Type and Number:
Japanese Patent JP2021028337
Kind Code:
A
Abstract:
To increase production of anti-inflammatory cells in human subjects using genetically unmodified stem cells that express Ang1 at high levels without the need for transfection of the cells with a nucleic acid expressing Ang1.SOLUTION: The present disclosure relates to stem cells which express high levels of Angiopoietin-1 (Ang1), and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.SELECTED DRAWING: None
Inventors:
SILVIU ITESCU
PAUL SIMMONS
PAUL SIMMONS
Application Number:
JP2020195123A
Publication Date:
February 25, 2021
Filing Date:
November 25, 2020
Export Citation:
Assignee:
MESOBLAST INT SARL
International Classes:
A61K35/28; A61P29/00; A61P43/00; C12N5/0775; C12N5/10
Domestic Patent References:
| JP2008514188A | 2008-05-08 | |||
| JP2011067175A | 2011-04-07 |
Foreign References:
| WO2012051210A2 | 2012-04-19 | |||
| WO2015155187A1 | 2015-10-15 |
Other References:
ANGIOGENESIS,2014,17(4),P.851-856,EPUB:2014-ARP-13, JPN6019037126, ISSN: 0004660691
INT.J.MOL.SCI.,2013,14(9),P.17986-18001, JPN6019037125, ISSN: 0004660692
INT.J.MOL.SCI.,2013,14(9),P.17986-18001, JPN6019037125, ISSN: 0004660692
Attorney, Agent or Firm:
Yasuhiko Murayama
Shinya Mitsuhiro
Tatsuhiko Abe
Shinya Mitsuhiro
Tatsuhiko Abe